Mitani K, Tsuboi I, Tanaka G, Yosioka S, Yokoyama S, Kobayashi Y, Nakajima H, Nagami T, Ogawa K, Wada K. Metastatic
small cell bladder cancer treated with sequential systemic therapy including pembrolizumab and amrubicin: A case report.
IJU Case Rep 2024;
7:127-130. [PMID:
38440697 PMCID:
PMC10909136 DOI:
10.1002/iju5.12684]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Accepted: 12/07/2023] [Indexed: 03/06/2024] Open
Abstract
Introduction
Small cell bladder cancer is a relatively rare tumor, representing <1% of all bladder tumors. Amrubicin monotherapy is used as second-line treatment for small cell lung cancer in Japan.
Case presentation
A 79-year-old woman presented with gross hematuria and was diagnosed with small cell bladder cancer (T2 or higher). Neoadjuvant chemotherapy with etoposide and cisplatin resulted in a partial response. Robot-assisted radical cystectomy was performed, and radical resection was achieved. As we identified metastasis in the pleura 1 year later, we administered carboplatin and etoposide, which resulted in a partial response. Although pembrolizumab was initiated as maintenance therapy, it was not effective. Amrubicin was given as third-line therapy, and stable disease was achieved without serious adverse effect for 6 months.
Conclusion
Although there is no established treatment for metastatic small cell bladder cancer, the current case report suggests the effectiveness of amrubicin in this setting.
Collapse